Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results

3 weeks ago

 ●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income…

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

3 weeks ago

Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in…

Sharps Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology Drug Delivery Systems

3 weeks ago

Sharps and Roncadelle are Joining Forces to Sell and Distribute their Securegard, SAFER, and Sologard Lines of Disposable Smart Safety…

American Oncology Network Announces Leaders Participating in ACCC’s Annual Meeting & Cancer Center Business Summit

3 weeks ago

Alti Rahman and Susan Sabo-Wagner were selected as panelists at the Association of Cancer Care Centers event in Washington, D.C.…

Clene to Present at the 36th Annual ROTH Conference

3 weeks ago

SALT LAKE CITY, March 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its…

Reviva to Present at the 36th Annual ROTH Conference

3 weeks ago

CUPERTINO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…

Strainsforpains, Inc. Investors Update: Strainsforpains, Inc. Showing Strong Revenue Growth

3 weeks ago

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- -- (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH) Strainsforpains, Inc. is…

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

3 weeks ago

The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key…

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

3 weeks ago

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses…

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

3 weeks ago

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…